Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs
BioSpace
Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.
pharminent
June 11, 2026 (Last updated: June 11, 2026)
BioSpace
Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.
